anastrozole / Generic mfg. - LARVOL DELTA

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial (SABCS 2025) - P3 | "Giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), was shown to be more potent than other SERDs (Liang 2021; Bardia 2023) and demonstrated superior antiproliferative activity vs anastrozole in the neoadj coopERA BC trial (Hurvitz 2023)... Pts with Stage I-III ER+ HER2- eBC were randomized 1:1 to giredestrant 30 mg oral daily (with an LHRH agonist in pre- and peri-menopausal women, and men) or standard-of-care ET (tamoxifen or aromatase inhibitor) for 5 years (yr)... lidERA BC is the first Phase III trial to demonstrate benefit with an oral SERD in eBC. Giredestrant tx resulted in a statistically significant and clinically meaningful IDFS improvement vs standard-of-care ET in ER+, HER2- eBC. OS trended in favor of the giredestrant arm, and DRFI was improved vs standard-of-care ET."

Clinical • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Ribociclib-induced vitiligo-like depigmentation: A case series of three breastcancer patients (EADV 2026) - "Materials and Methods We report three female patients, aged 43, 45, and 70 years, treated for HR+/HER2− metastatic breast cancer with ribociclib combined with fulvestrant, letrozole, and anastrozole, respectively. Awareness of this entity is essential to prevent misdiagnosis and avoid unnecessary interruption of effective oncological therapy. Close collaboration between dermatologists and oncologists is important to optimize patient management while maintaining effective anticancer treatment."

Clinical • Breast Cancer • Dermatology • Endocrine Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Oncology • Solid Tumor • Vitiligo • HER-2

Safety profile of exemestane vs. anastrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports (ESMO 2026) - No abstract available

Case report • Clinical • Real-world • Real-world evidence • Review • Oncology

OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) - P3 | N=250 | Active, not recruiting | Sponsor: Tolmar Inc. | Trial completion date: Apr 2026 ➔ Nov 2026 | Trial primary completion date: Apr 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial (ESMO 2022) - P3 | "Clinical trial identification NCT03966898. Conclusions Adding dalp to letrozole/anastrozole significantly prolonged PFS in HR+/HER2- ABC, with manageable toxicities. Dalp is the 4 th CDK4/6 inhibitor showing survival benefit with letrozole or anastrozole in untreated HR+/HER2- ABC, or with fulvestrant in pretreated HR+/HER2- ABC, in addition to palbociclib, ribociclib and abemaciclib."

Clinical • Late-breaking abstract • P3 data • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. (PubMed, Ann Oncol) - "Abemaciclib combined with an NSAI resulted in clinically meaningful improvement in median OS (ITT: 13.1 months; sVD: 14.9 months) in patients with HR+ HER2- ABC; however, statistical significance was not reached."

Clinical • Journal • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

The Great Masquerader: Metastatic Breast Cancer Presenting as Decompensated Cirrhosis (ACG 2026) - "She had been receiving anastrozole and was transitioned to fulvestrant. During fulvestrant monotherapy, she developed skull metastases, prompting addition of abemaciclib...Clinicians should consider GI metastases in patients with prior breast cancer who present with new nonspecific GI symptoms, including evidence of new cirrhosis. Early recognition and management are critical for improved outcomes."

Metastases • Acute Kidney Injury • Breast Cancer • CNS Disorders • Colonic Polyps • Colorectal Cancer • Endocrine Disorders • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Metabolic Disorders • Nephrology • Oncology • Peritoneal Cancer • Portal Hypertension • Renal Disease • Solid Tumor • GATA3 • GCDFP-15 • HER-2 • Mammaglobin • PGR

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. (ASCO 2025) - P3 | " Pts with HR+/HER2– ABC who had received ≥6 months of 1L AI (anastrozole/letrozole) + CDK4/6i (abemaciclib/palbociclib/ribociclib) were enrolled and had ctDNA tested for ESR1m every 2–3 months, coinciding with routine imaging. Camizestrant + CDK4/6i guided by emergence of ESR1m during 1L AI + CDK4/6i in pts with HR+/HER2– ABC resulted in a statistically significant and clinically meaningful improvement in PFS. SERENA-6 is the first global Phase 3 trial to demonstrate clinical utility of using ctDNA to detect and treat emerging resistance, ahead of disease progression. These findings represent a potential new treatment strategy to optimize and improve 1L patient outcomes."

Circulating tumor DNA • Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

A Colonic Metastasis of Breast Cancer Discovered During Routine Surveillance Colonoscopy (ACG 2026) - "Coupled with significantly elevated tumor markers (CEA 12.3, CA 27-29 301.8, CA 15-3 200), the patient was initiated on a targeted therapeutic regimen of Abemaciclib (CDK4/6 inhibitor) and Anastrozole (aromatase inhibitor) for hormonal control, alongside Denosumab to manage bone disease and protect skeletal integrity. Figure: Ileocecal Valve with Cecum Colitis with noticeable erythema and mosaic pattern. Figure: Pathology samples noted for patchy infiltrate medium to large-sized cells with occasional nucleoli and abundant cytoplasm."

Breast Cancer • Colorectal Cancer • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Inflammatory Bowel Disease • Oncology • Solid Tumor • Cancer antigen 27-29 • GCDFP-15 • HER-2 • Mammaglobin

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (SABCS 2025) - "Methods SERENA-6, a randomized, double-blind, phase 3 trial, enrolled pts with HR+/HER2- ABC who had received ≥6 months of 1L AI (anastrozole/letrozole) + CDK4/6i (palbociclib/ribociclib/abemaciclib). No new safety signals were observed. These results further support an early switch to CAMI + CDK4/6i during 1L therapy to delay disease progression."

Circulating tumor DNA • Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Recurrent Small Bowel Obstruction With Initially Unrevealing Endoscopy Reveals Diffuse Gastrointestinal Metastatic Lobular Breast Carcinoma (ACG 2026) - "Case Description/ A 68-year-old woman with Stage IIIC invasive lobular breast carcinoma (ER-positive, HER2-negative) status post mastectomy, chemotherapy, radiation, anastrozole, and abemaciclib presented with progressive epigastric pain, nausea, vomiting, and diarrhea. Repeat endoscopic assessment with liberal biopsy may be necessary to establish the diagnosis. Figure: Dilation of small bowel with transition point"

Metastases • Breast Cancer • Gastric Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Small Intestinal Carcinoma • Solid Tumor • ER • HER-2

Synchronous Triple Malignancy Presentation of Multiple Myeloma and Prefibrotic Primary Myelofibrosis in a Patient With Mucinous Breast Carcinoma: A Case Report From Rural South Africa. (PubMed, Case Rep Hematol) - "The patient commenced therapy with melphalan and prednisone for myeloma and anastrozole for breast carcinoma, with multidisciplinary input guiding treatment sequencing. Triple synchronous primary malignancies are exceedingly rare and diagnostically challenging. This case emphasises the necessity of a systematic, multidisciplinary approach to evaluation and management, even in low-resource settings, to ensure accurate diagnosis and optimal coordination of care across multiple oncologic pathologies."

Journal • Breast Cancer • Hematological Disorders • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Multiple Myeloma • Musculoskeletal Diseases • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Plasmacytoma • Solid Tumor • Thrombocytosis • HER-2 • JAK2 • PGR

NeoPalAna: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - P2 | N=84 | Active, not recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Aug 2026 ➔ Nov 2027

Trial completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

When âAlternativeâ Becomes Harmful: Liver Injury Triggered by Off-Label Ivermectin and Mebendazole in Cancer Self-Treatment (ACG 2026) - "After previously declining conventional therapy, she began anastrozole in August 2025 and subsequently added metformin, ivermectin, and mebendazole as alternative treatment. Early recognition and withdrawal of the offending medications is critical to mitigating further injury, avoiding unnecessary interventions, and facilitating recovery. This case highlights the importance of thorough medication history and the need to consider uncommon drug related etiologies."

Breast Cancer • Dyslipidemia • Hepatology • Liver Failure • Oncology • Solid Tumor

A CVID Mimic: A Rare Complication of Long-Term Anti-CD20 Therapy (ACG 2026) - "Case Description/ We present this 76 year old female with history of Stage IV mantle cell lymphoma for several years on rituximab every 8 weeks for disease control with known lymphadenopathy, positive breast/gastrointestinal tract metastatic biopsies and was recently diagnosed with breast cancer and s/p mastectomy was initially placed on pembrolizumab but later discontinued due to intolerance and continued on anastrazole. Figure: Upper endoscopy demonstrating oedematous and erythematous duodenal mucosa Figure: Nodular duodenal mucosa with inflammatory changes. Biopsies demonstrated villous atrophy with loss of B cells on CD20/PAX5 staining and sparse plasma cells"

Breast Cancer • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Primary Immunodeficiency • Solid Tumor • PAX5 • SDC1

A Bleeding Ulcer That Wasn't: Gastric Metastasis From Invasive Ductal Breast Carcinoma (ACG 2026) - "Her oncologic course was marked by axillary nodal recurrence in 2017, followed by progressive metastatic disease involving lung, bone, liver, and brain, treated with anastrozole, letrozole, fulvestrant/everolimus, alpelisib, trastuzumab deruxtecan, and elacestrant. Gastroenterologists evaluating GI bleeding in patients with breast cancer history should pursue targeted biopsy with breast-directed immunohistochemistry, as accurate classification carries direct therapeutic implications. Figure: Endoscopic findings showing a 2.5 cm ulcer on the greater curvature of the proximal body and multiple additional ulcers up to 1.5 cm along the antrum, distal body, and proximal body of the stomach."

Breast Cancer • Gastric Cancer • Gastrointestinal Disorder • HER2 Positive Breast Cancer • Oncology • Peptic Ulcer • Solid Tumor • CDH1 • GATA3 • PGR

Supraphysiological Testosterone Differentially Regulates Aortic Atheroma and Cardiac Remodelling in the Testicular Feminised Mouse. (PubMed, Cells) - "Male Tfm mice and AR-intact XY littermate controls were fed a cholesterol-enriched diet for 28 weeks and received fortnightly intramuscular injections of saline or supraphysiological testosterone, alone or in combination with fulvestrant (oestrogen receptor antagonist) or anastrozole (aromatase inhibitor). In contrast, supraphysiological testosterone increased heart weight, cardiomyocyte size and expression of hypertrophic markers exclusively in XY mice, with no evidence of cardiac remodelling in Tfm mice. Collectively, these findings demonstrate divergent tissue-specific cardiovascular actions of testosterone, whereby supraphysiological exposure promotes AR-dependent cardiac remodelling without conferring additional vascular benefit, supporting maintenance of physiological testosterone concentrations during TTh."

Journal • Preclinical • Atherosclerosis • Cardiovascular

Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2_) primary breast cancer (BC): CheckMate 7A8 (ESMO-BC 2022) - P2 | "Neoadjuvant NIVO + PALBO + ANA showed a higher incidence of grade ≥3 hepatic TRAEs than historical single-agent safety profiles. These findings show a potential safety risk for the use of endocrine therapy with PD-1 + CDK 4/6 blockade."

Clinical • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • ER • HER-2

Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08) (SABCS 2023) - P1b | "Safety profiles for T-DXd-ET combinations were generally comparable to T-DXd monotherapy and manageable with dose modification and routine clinical practice. T-DXd in combination with anastrozole or fulvestrant was active in first- or second-line treatment of patients with HER2-low HR+ mBC."

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. (ASCO 2024) - P3 | "Background: NATALEE assessed ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) vs NSAI alone in pts with HR+/HER2− EBC at increased risk of recurrence, including pts with N0 disease, and showed a statistically significant invasive disease-free survival (iDFS) benefit... Pts with stage II/III HR+/HER2− EBC were randomized (R) 1:1 to RIB 400 mg/d (3 wk on/1 wk off for 36 mo) + NSAI (letrozole or anastrozole for ≥60 mo) or NSAI alone. Men and premenopausal women received goserelin... This analysis showed a consistent efficacy benefit and manageable safety profile of RIB + NSAI vs NSAI alone in pts with N0 disease in NATALEE. The 3y iDFS, DDFS, and DRFS rates in the control arm at this early follow-up underscore the risk of recurrence for the N0 subgroup. These findings support the use of RIB in pts with HR+/HER2− EBC at increased risk of recurrence, including pts with N0 disease."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial (ESMO 2024) - P3 | "We present efficacy and safety data of an exploratory analysis with all pts now off RIB. Pts were randomized 1:1 to RIB (400 mg/d; 3 wk on/1 wk off for 3 y) + NSAI (letrozole 2.5 mg/d or anastrozole 1 mg/d, for 5 y) or NSAI alone. Men and premenopausal women received goserelin... In this 4-y landmark analysis, RIB + NSAI reduced the risk of invasive and distant disease recurrence by 28.5% compared with NSAI. This benefit was maintained after the planned 3-y RIB treatment duration, resulting in an increasing absolute benefit up to 4 y. These results further support the addition of RIB to adjuvant NSAI in a broad population of pts with HR+/HER2− EBC at risk of recurrence."

Clinical • Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

TACTIVE-N: Phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (BC) (ESMO 2025) - P2 | "Conclusions Neoadjuvant vepdegestrant was well tolerated and demonstrated biological and clinical activity in postmenopausal women with ER+/HER2- localized BC. Vepdegestrant led to robust ER protein degradation in tumor tissue, supporting its pharmacodynamic effect in pts with BC."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC). (ASCO 2022) - P2 | "Funded by: Pharmaceutical/Biotech Company. ONA-XR was well tolerated and exhibited a 12-month PFS rate of 20.1% and a CBR of 35.7% in patients with GCT. No objective responses were observed. Cohorts 1-3 have closed to accrual, with 2 patients continuing active treatment for >18 months."

Pan tumor • Anemia • Cardiovascular • Endometrial Cancer • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Nephrology • Neutropenia • Oncology • Ovarian Serous Adenocarcinoma • Pain • Solid Tumor • PGR

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. (PubMed, Lancet Oncol) - P2 | "Giredestrant offers encouraging anti-proliferative and anti-tumour activity and was well tolerated, both as a single agent and in combination with palbociclib. Results justify further investigation in ongoing trials."

Journal • P2 data • Breast Cancer • Cardiovascular • Estrogen Receptor Positive Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Myocardial Infarction • Neutropenia • Oncology • Solid Tumor • ER • HER-2 • PGR